Thermal Stabilization of Viral Vaccines in Low-Cost Sugar Films
Vaccines are critical in preventing infectious diseases, but most require continuous
refrigeration—a “cold chain” that’s expensive and logistically challenging, especially in
developing countries. The best solution is the use of pullulan and trehalose sugar films to
stabilize vaccines thermally, allowing storage at elevated temperatures without losing
effectiveness
Innovation Behind the Technology
This method involves encapsulating viral vaccines—such as live-attenuated Herpes Simplex
Virus type 2 (HSV-2) and inactivated Influenza A—in a blend of pullulan (a polysaccharide)
and trehalose (a protective sugar). When dried, the film preserves the virus's structure by
replacing water molecules and forming a glassy matrix, thus preventing degradation at high
temperatures. This approach simplifies vaccine preservation by using affordable, FDA-
approved materials and avoids complex freeze-drying equipment.
Many viruses—including SARS-CoV-2—coat their spike proteins with glycans derived from host
cells. These sugar shields help the virus evade immune detection. The novel approach uses enzymatic
deglycosylation to remove these glycans, revealing a low-mutation "stalk" region of the spike protein.
This exposed region becomes the immune system’s new target. In early animal studies with mice and
hamsters, vaccines using this method generated higher-titer and more diverse antibodies than
conventional variant-specific vaccines
Potential Impacts
Positive: Dramatically reduces dependence on cold chain logistics, lowering vaccine
wastage and cost. The study demonstrated that HSV-2 remained effective for at least
2 months at 40 °C, and influenza vaccine retained immunogenicity for 3 months at the
same temperature.
This could vastly improve vaccine access in remote regions. Pullulan’s water
solubility also enables direct administration—potentially even via mucosal routes—
without needing reconstitution.
Negative: Scaling this method to different vaccine types like mRNA or adenoviral
vectors may require further optimization. Long-term safety and immunogenicity
across diverse populations still need validation, and manufacturing still must meet
strict regulatory standards.
Effect on Daily Life
Imagine living in a rural area without reliable electricity: vaccines could be stored on a shelf
at room temperature, then administered quickly during public health campaigns. This would
reduce lost doses, lower costs, and increase immunization coverage—making critical
vaccines more reliable and accessible for families worldwide.
Vaccines are critical in preventing infectious diseases, but most require continuous
refrigeration—a “cold chain” that’s expensive and logistically challenging, especially in
developing countries. The best solution is the use of pullulan and trehalose sugar films to
stabilize vaccines thermally, allowing storage at elevated temperatures without losing
effectiveness
Innovation Behind the Technology
This method involves encapsulating viral vaccines—such as live-attenuated Herpes Simplex
Virus type 2 (HSV-2) and inactivated Influenza A—in a blend of pullulan (a polysaccharide)
and trehalose (a protective sugar). When dried, the film preserves the virus's structure by
replacing water molecules and forming a glassy matrix, thus preventing degradation at high
temperatures. This approach simplifies vaccine preservation by using affordable, FDA-
approved materials and avoids complex freeze-drying equipment.
Many viruses—including SARS-CoV-2—coat their spike proteins with glycans derived from host
cells. These sugar shields help the virus evade immune detection. The novel approach uses enzymatic
deglycosylation to remove these glycans, revealing a low-mutation "stalk" region of the spike protein.
This exposed region becomes the immune system’s new target. In early animal studies with mice and
hamsters, vaccines using this method generated higher-titer and more diverse antibodies than
conventional variant-specific vaccines
Potential Impacts
Positive: Dramatically reduces dependence on cold chain logistics, lowering vaccine
wastage and cost. The study demonstrated that HSV-2 remained effective for at least
2 months at 40 °C, and influenza vaccine retained immunogenicity for 3 months at the
same temperature.
This could vastly improve vaccine access in remote regions. Pullulan’s water
solubility also enables direct administration—potentially even via mucosal routes—
without needing reconstitution.
Negative: Scaling this method to different vaccine types like mRNA or adenoviral
vectors may require further optimization. Long-term safety and immunogenicity
across diverse populations still need validation, and manufacturing still must meet
strict regulatory standards.
Effect on Daily Life
Imagine living in a rural area without reliable electricity: vaccines could be stored on a shelf
at room temperature, then administered quickly during public health campaigns. This would
reduce lost doses, lower costs, and increase immunization coverage—making critical
vaccines more reliable and accessible for families worldwide.
